Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04574063 Active, not recruiting - Breast Cancer Clinical Trials

PIONEER Study of Lifestyle Intervention to Reduced Breast Cancer Risk

PIONEER
Start date: September 16, 2020
Phase: N/A
Study type: Interventional

A randomised controlled trial in which women discharged from the symptomatic breast clinic, who are above population risk (according to Tyrer Cuzick) will be asked to create lifestyle related goals. They will be told their estimated risk of developing breast cancer and will be randomised to one of three interventions: - Breast cancer risk leaflet only - lifestyle website - lifestyle website plus group coaching. Fifty per cent of women will also be randomised to have Single Nucleotide Polymorphisms (SNPs) performed, and these will be incorporated into their risk score. The primary end point will be whether or not women achieve their lifestyle goal.

NCT ID: NCT04573231 Recruiting - Breast Cancer Clinical Trials

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Start date: May 24, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.

NCT ID: NCT04572295 Active, not recruiting - Breast Neoplasms Clinical Trials

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Start date: October 9, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.

NCT ID: NCT04571437 Recruiting - Breast Cancer Clinical Trials

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

B-001
Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.

NCT ID: NCT04571307 Recruiting - Breast Disease Clinical Trials

Cryotherapy in Breast B3 Lesions

Start date: September 15, 2021
Phase: N/A
Study type: Interventional

To determine the feasibility of cryotherapy for B3 fibroepithelial lesions

NCT ID: NCT04570956 Recruiting - Breast Carcinoma Clinical Trials

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Start date: July 26, 2021
Phase: Phase 2
Study type: Interventional

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

NCT ID: NCT04569955 Recruiting - Breast Cancer Clinical Trials

Knowledge and Perception of Clinical Trial Participation in Breast Cancer Patients in Egypt

Start date: July 20, 2020
Phase:
Study type: Observational

- Clinical trials are essential to translate new therapy concepts or rather any intervention into the medical routine. Beside the well designed trial protocol, the success of clinical trials depends on patient recruitment and participation. - This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries.

NCT ID: NCT04569747 Recruiting - Breast Cancer Clinical Trials

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

ADEPT
Start date: January 11, 2021
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: - A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) - Hormonal (endocrine) Treatment

NCT ID: NCT04568941 Not yet recruiting - Breast Cancer Clinical Trials

Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

Sentinel lymph node biopsy (SLNB) has become a mainstay surgery method in breast cance, and the identified number of sentinel lymph nodes determines its accuracy for axillary status. Retrospective study indicated that preoperative tumor biopsy results in more detected sentinel lymoh nodes. The clinical trail is designed to compare the effect of three tumor biopsy methods (preoperative vacuum-assisted biopsy, core needle biopsy, and intraoperative excisional biopsy) for sentinel lymph nodes.

NCT ID: NCT04568902 Active, not recruiting - Breast Neoplasms Clinical Trials

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Start date: September 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of study is to determine tolerability and safety profile of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer, and also to confirm the dose applicability to Japanese.